Novo Nordisk Seeks Approval for Oral Weight-Loss Drug in China
Danish pharma giant Novo Nordisk has submitted its oral weight-loss drug for regulatory review in China.
2026年9月3日
/ DANGDI / DANGDI / DANGDI /Danish healthcare giant Novo Nordisk is expanding its reach in China. China's drug regulator has accepted the company's application for an oral weight-loss drug.
This treatment is an oral version of Wegovy. The drug uses the active ingredient semaglutide. Wegovy is currently available as an injection. An oral option gives patients a new choice.
The application must now pass a regulatory review. Acceptance does not mean the product is approved yet. A market launch depends on the final review results.
Novo Nordisk has operated in China for over 30 years. China is a major market for obesity treatments. Competition in China is growing fast. Novo Nordisk faces rivals from US company Eli Lilly and Chinese drugmakers.
This development shows strong ties between Nordic healthcare innovation and China. It offers useful background for local professionals in life sciences. ScandAsia reported this story based on reports from Reuters.
Source: Scandasia
